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Abstract: In this report, we present a case involving the discovery of metastatic melanoma within a mid-
right back mass with the clinical presentation of an epidermoid cyst, but the histological qualities of a 
lymph node. A 43-year-old male presented with a 5 cm x 5 cm cyst-like mass on his mid-right back that had 
become painful over the last year and consequently underwent three surgical procedures. First, initial 
excision of the back mass and histological examination resulted in a diagnosis of metastatic melanoma 
without epidermal involvement. This was followed by re-excision of the back mass site and sentinel node 
excision, and finally, lymph node dissection of the right axilla. Of the lymph nodes examined, the sentinel 
node in the right axilla alone showed evidence of melanoma. The absence of a primary lesion or any 
histological evidence of regression in a presumed primary site resulted in a diagnosis of melanoma of 
unknown primary, or occult primary melanoma. To our knowledge, this is the first documented case of an 
occult primary melanoma presenting as a single mass representing a lymph node in the back. 
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Introduction 
Melanoma of unknown primary (MUP), also known as occult primary melanoma, is a term applied to a 
metastatic melanoma that is initially discovered in a secondary site (such as a lymph node, distant skin or 
subcutaneous tissue, or visceral site) rather than as a primary cutaneous, mucosal, or ocular tumor [1]. As 
the name suggests, a patient with MUP has no evidence of a primary lesion. MUP has an incidence of 3.2%, 
is found in males twice as often as females, and most often presents in the 4th and 5th decades of life. In a 
review of 4433 MUP patients, 1067 patients were found to have lymph node involvement in the axilla, 
neck, groin, parotid gland, or some combination of those sites [2]. 
 There are two prevalent theories behind MUP. The first, and less likely, is that MUP arises from 
melanocytes that have migrated to a lymph node and become malignant. The second, and more accepted, 
involves spontaneous partial or complete regression of the primary tumor after it has metastasized [3]. 
Though 49 cases of completely regressed primary cutaneous melanoma have been documented, a presumed 
primary site with histological evidence of regression is not always possible to find in a patient, leading to a 
more general diagnosis of MUP [4].  
Case Report 
A 43-year-old male presented with a 5 cm x 5 cm soft, cyst-like mass on his mid-right back, attached 
to the skin with a soft apex and possible punctum. Though this mass had been present for 4-5 years, 
the patient reported that it had increased in size over the last year and had become painful. The patient 
noted one episode of purulent discharge but denied any other complaints. The patient denied any past 
medical history, past surgical history, or family history of cancer (skin or otherwise).  
 
  
  
Figure 1 Histology of the patient’s original back excision. A. Positive S-100 stain. 400x. B. Positive Melan-A stain. 400x. C. 
Melanoma tumor with surrounding capsule and scattered lymphoid tissue. 100x. D. Pigmented melanoma cells within the 
mass with H&E stain. 400x. 
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 The mass was excised completely and no sebum was noted. The patient tolerated the 
procedure well. Grossly, the specimen was a focally hemorrhagic soft tissue mass measuring 5 cm in 
diameter. Histopathological examination resulted in a diagnosis of malignant melanoma in the dermis 
and subcutaneous tissue, with no involvement of the epidermis. The neoplasm stained positive for 
S100 and Melan-A [Figure 1], and stained negative for cytokeratin. The neoplasm was diffusely 
positive for BRAF-V600E, which correlates with a V600E BRAF mutation. Though the mass was 
initially thought to be an epidermoid cyst, histological examination showed evidence of a capsule 
surrounding the tumor with patches of lymphoid tissue along the perimeter [Figure 1c], suggesting the 
tumor may have grown within a lymph node.  
 
  
Figure 2 Lymphoscintigrams performed 1 week apart, both showing activity limited to at least 3 foci in the right axilla. A: 
right lateral view, first scan. B: anterior dynamic view, repeat scan. 
 
 In follow-up visits, the patient denied any complaints and the excision wound healed well, 
without drainage, edema, or erythema. Per the pathologist’s recommendation, the decision was made 
to perform a wide re-excision of the site of melanoma to determine the depth of invasion of the 
specimen, which would help with our initial diagnosis. Prior to this second surgery, the patient 
underwent a PET/CT scan followed by a lymphoscintigram. The PET/CT showed no abnormal 
fluorodeoxyglucose (FDG) uptake and no evidence of regional or metastatic disease. The 
lymphoscintigram showed three discrete foci of activity in the right axillary region only. A repeat 
lymphoscintigram performed 1 week later confirmed the findings in the right axilla and no new areas 
of activity were identified. [Figure 2] 
 The re-excision and depth of invasion study were performed approximately two months after 
the original excision. The back re-excision included the fascia of the back and a skin margin of > 2 cm. 
[Figure 3] The sentinel lymph node was localized by nuclear injection in the right axilla. Methylene 
blue was injected after the anesthetic induction, and a radiotracer was used to place the incision in the 
appropriate area. The blue and radioactive sentinel lymph node was visualized and excised [Figure 4]. 
The patient tolerated the procedure well and there were no complications. 
 Both specimens were sent for histopathological examination. The back mass excision 
showed no evidence of residual melanoma, while the sentinel lymph node contained an 
intraparenchymal microscopic focus of metastatic melanoma measuring 0.6 cm in diameter without 
extracapsular extension. This was confirmed with positive Melan-A and S100 immunostains [Figure 
5]. 
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Figure 3 Surgical re-excision of the back mass site with a skin margin of >2 cm.  
Figure 4 Sentinel lymph node excised from the right axilla. 
 
  
Figure 5 Histology of the excised sentinel node. A. Positive S100 stain. 100x. B. Positive Melan-A stain. 100x. 
 
 Following the back re-excision and depth of invasion study, it was noted that the patient had 
moderate edema at the proximal and distal ends of the back incision, but he denied any pain or fever. 
The axillary incision healed well with no signs of infection. The patient was referred to medical 
oncology and a chest x-ray, brain CT without contrast, and an abdomen/pelvis CT with contrast were 
ordered to rule out distant metastasis. The results of all three studies were unremarkable. 
 The patient’s melanoma was classified as Stage IIIA (T3N1aM0) and the medical oncologist 
recommended a lymph node dissection of the right axilla based on the positive lymphoscintigram. The 
axillary fat pad containing level I and level II nodes was separated from the axillary tail of the breast 
and excised, and it measured 12 cm x 6 cm x 2.5 cm. A #10 Jackson-Pratt (JP) drain was left in place. 
The procedure was tolerated well and there were no complications. The patient was able to manage the 
JP drain appropriately at home and this drain was removed on postoperative day 11. 
 Histopathological examination showed that the 13 lymph nodes removed were all negative 
for metastatic melanoma. The patient will continue to follow up with the surgery and medical 
oncology departments periodically and no further treatments or procedures are scheduled at this time. 
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Discussion 
MUP has been well-documented in the literature, but this case is unique in that the patient’s melanoma 
metastasized from a currently undetectable primary tumor to an apparent lymph node in his mid-right 
back, presenting as a 5 cm x 5 cm mass. From the back, metastasis was limited to one lymph node in 
the right axilla, which also added to the complexity of this case. This pathology agrees with 
established lymphatic drainage maps [5]. Although the posterior trunk is not a region with established 
lymph node chains, it is one of the most common locations of interval nodes, which can lie anywhere 
along the path of a lymphatic collecting vessel [5]. Given this knowledge and the histopathological 
characteristics of the excised mass, it is likely that the patient’s melanoma infiltrated an interval node 
in the back. Previous reports of MUP with lymph node involvement have only listed the axilla, groin, 
neck, and parotid gland as observed locations [2], and we have been unable to find any prior reports of 
MUP discovery in an interval node in the back.  
 At this point, no further treatments are recommended since surgical resection of both 
detectable metastatic sites was successful. Had the patient’s solitary mass been non-resectable, the 
presence of a BRAF mutation would have made him eligible for a BRAF inhibitor treatment such as 
dabrafenib [6]. Should the patient experience a recurrence in the future, BRAF inhibitor therapy may 
be considered. Per the National Comprehensive Cancer Network, interferon alfa or high-dose 
ipilimumab are also potential adjuvant treatments for Stage III melanoma with a positive sentinel node 
[7].  
 Because the histopathological study of the initial back mass excision showed no epidermal 
involvement, an alternate diagnosis that was considered was primary dermal melanoma (PDM), where 
the primary tumor originates in the dermis, subcutaneous tissue, or both [1]. PDM makes up <1% of 
all melanomas and does not metastasize, which likely contributes to the higher 5-year survival rates 
observed in PDM patients compared to primary cutaneous melanoma or MUP [8]. After the patient’s 
sentinel node tested positive for S100 and Melan-A, PDM was ruled out. One PDM cohort study 
found that all 9 of their subjects tested negative for BRAF-V600E, for which our patient tested 
positive. Teow et al. acknowledge that their sample size is too small to determine whether the absence 
of BRAF-V600E is a distinguishing characteristic of PDM, but future cases of PDM should be tested 
for BRAF mutations [9]. No reliable histopathological or immunohistochemical distinction between 
PDM and metastatic melanoma has been established, and an increased sampling of PDM patients may 
support BRAF-V600E as a candidate. 
Conclusion 
In summary, we have documented a case of melanoma of unknown primary presenting as a single 
mass on the mid-right back with histopathological characteristics of a lymph node. This was 
unexpected given its anatomic location, leading us to believe this is an unusual case where a MUP has 
infiltrated an interval lymph node in the back. 
Consent 
The patient signed a standard consent form allowing the authors to use both his medical records and 
images from the case in his writeup. We would like to thank him for his cooperation. 
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Abbreviations 
MUP: melanoma of unknown primary 
FDG: fluorodeoxyglucose 
JP: Jackson-Pratt 
PDM: primary dermal melanoma 
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